EFG Asset Management (EFGAM) has added to its UCITS range with the launch of the New Capital Healthcare Disruptors Fund.
Benchmarked against the MSCI World Health Care index, the Fund will have up to 30 holdings across the market cap spectrum. It is managed by Mike Clulow, and EFGAM’s US growth equity team, Tim Butler, Joel Rubenstein and Chelsea Wiater, all of whom are based in Portland, Oregon.
The team seeks to identify innovative healthcare companies that are seizing market share through disruptive technologies and services. Rather than focusing on single segments of the healthcare sector, the team looks across the spectrum. This includes:
• Biopharmaceuticals (eg gene therapy, immunotherapy and genetically targeted treatments)
• Medical devices (eg robotics, miniaturisation and wearables)
• Healthcare services (eg telemedicine and remote monitoring)
• Pharmaceutical outsourcing (eg cloud solutions, data analytics and artificial intelligence)
Mike Clulow, Portfolio Manager, New Capital Healthcare Disruptors Fund, says: “We search for companies that are displacing legacy participants facing patent expirations and product obsolescence. Covid-19 has accelerated this adoption cycle, as next generation products may drive more cost-effective outcomes, and potentially minimize the likelihood of viral or bacterial transmission. The broader use of telemedicine, the shift towards minimally invasive procedures, and the widespread adoption of wireless devices and wearable products all reflect this trend.”
Moz Afzal, Global Chief Investment Officer, EFGAM, says: “We are excited to be launching this new strategy at this time. As the world navigates the current crisis and looks ahead to a post-pandemic era, we believe the dramatic transformation in the healthcare sector, driven by the need to lower healthcare costs, will lead to a new wave of disruptive technologies and business models. These disruptive trends should provide our clients with fresh and exciting investment opportunities.”
